Aspen sells menopause treatment Ovestin’s European rights for €197m

Aspen expects a R2bn profit on the disposal but will retain a 10-year manufacturing and supply role

Aspen sells menopause treatment Ovestin’s European rights for €197m
Aspen expects a R2bn profit on the disposal but will retain a 10-year manufacturing and supply role